Naurex

Developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system

Launch date

2008

Employees

Ownership

subsidiary, venture capital

Firm valuation

Evanston Illinois (HQ)

http://naurex.com

https://twitter.com/allergan https://www.linkedin.com/company/naurex-inc.

Date	Investors	Amount	Round
Feb 2011	Takeda Ventures	$1.1m	Debt
May 2011	Adams Street Partners Latterell Venture Partners Takeda Ventures Pathofinder Genesys Capital Druid BioVentures	$18m	Series A
Dec 2012	Adams Street Partners Latterell Venture Partners Savitr Capital Pathofinder Baxter International Genesys Capital Druid BioVentures	$38m	Series B
May 2014	Shire Lundbeck Takeda Baxter International	$25m	Series C
Dec 2014	Adams Street Partners Cowen Group Latterell Venture Partners Takeda Ventures Savitr Capital Portal Capital Baxter Ventures Pathofinder Genesys Capital EcoR1 Capital Sabby Capital Goudy Park Capital Druid BioVentures	$80m	Series C
Jul 2015	Allergan	$560m Valuation: $560m	Acquisition
Total Funding		$161m